期刊文献+

CK-19在甲状腺乳头状癌及甲状腺乳头状增生患者外周血中的表达 被引量:2

Expression of CK-19 in peripheral blood of patients with papillary thyroid carcinoma and papillary thyroid hyperplasia
下载PDF
导出
摘要 目的检测细胞角蛋白(CK-19)在甲状腺乳头状癌(PTC)和结节性甲状腺肿并乳头状增生患者血清中的表达,筛选甲状腺乳头状癌的辅助诊断指标。方法采用酶联免疫吸附试验(ELISA)法检测结节性甲状腺肿并乳头状增生25例、乳头状癌25例及正常人25例血清中CK-19的表达。结果CK-19表达水平以甲状腺乳头状癌高,结节性甲状腺肿伴乳头状增生居中,正常人低,三者差异有显著性(F=8.371,P<0.05);CK-19表达水平在甲状腺乳头状癌伴淋巴结转移比无伴淋巴结转移者更高,两者差异有显著性(t=5.371,P<0.05)。结论甲状腺乳头状癌患者外周血中CK-19表达率增高;CK-19对于甲状腺乳头状癌伴淋巴结转移的诊断具有一定的指导作用。 Objective To detect serum cytokeratin( CK - 19) in patients with papillary thyroid carcinoma(PTC) and nodular goiter with papillary hyperplasia, in order to suggest a diagnostic indicator for thyroid papillary carcinoma. Methods CK - 19 expression was determined in 25 cases of nodular goiter with papillary hyperplasia, 25 cases of papillary carcinoma, and 25 healthy subjects with enzyme - linked immunosorbent assay( ELISA). Results CK - 19 expression level was high in papillary thyroid carcinoma, middle in nodular goiter with papillary hyperplasia, and low in healthy subjects( F = 8. 371, P 〈 0.05 ). CK - 19 expression level in papillary thyroid carcinoma with lymph node metastasis was higher than that in papillary thyroid carcinoma without lymph node metastasis ( t = 5. 371, P 〈 0.05 ). Conclusion CK - 19 expression is increased in patients with papillary thyroid carcinoma. CK - 19 plays a guiding role in the diagnosis of papillary thyroid carcinoma with lymph node metastasis.
作者 魏杨辉 黄耀
出处 《临床和实验医学杂志》 2009年第9期5-6,共2页 Journal of Clinical and Experimental Medicine
基金 2008年福田区公益性科研计划项目立项FTWS058
关键词 细胞角蛋白 甲状腺乳头状癌 血清 酶联免疫吸附试验法 Cytokeratin Papillary thyroid carcinoma Serum Enzyme -linked immunosorbent assay
  • 相关文献

参考文献2

二级参考文献8

  • 1中山医科大学 同济医科大学.外科病理学,第2版[M].武汉:湖北科学技术出版社,1998.1299-304.
  • 2[1]Rosai J, Carcangin ML, Delellis RA. Atlas of tumor pathology: tumors of the thyroid gland. AFIP 3rd series, Fascicle 5,1992. 100
  • 3[2]Hedinger Chr, Williams ED, Sobin LH. Histological typing of thyroid tumor. 2nd ed, New York:Springer, 1998
  • 4[3]Baloch ZW, Abraham S, Roberts S et al. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol, 1999, 30:1166
  • 5[4]Nasser SM, Pitman MB, Pilch BZ et al. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining. Cancer, 2000,90:307
  • 6[5]Miettinen M, Kovatich AJ, Karkkainen P. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Virchows Arch, 1997,431:407
  • 7廖松林.甲状腺常见疾病的病理诊断及鉴别诊断[J].临床与实验病理学杂志,2000,16(6):510-512. 被引量:6
  • 8刘勇,苏祖兰,龙捷,唐录英,何丹.367例甲状腺疾病临床病理诊断分析[J].临床与实验病理学杂志,2001,17(3):238-240. 被引量:24

共引文献36

同被引文献41

  • 1杨燕初,陆竞艳,张莹,史琳,韦敏怡.甲状腺乳头状癌CD151和CK19mRNA表达及意义[J].临床与实验病理学杂志,2007,23(3):331-333. 被引量:5
  • 2周庚寅,觉道健一,主编.甲状腺病理及临床[M].北京:人民卫生出版社,2005.155-157.
  • 3Pradhan GB, Shrestha R, Shrestha S,et al. The incidence of thyroidcarcinoma in multinodular goiter, prospective study [j]. Nepal MedColl J. 2011,13(3):169-71.
  • 4FerlitoA, Partridge Brennan J, et al. Lymph node micrometastasesin head and neck cancer; a r eview[j]. Acta Otolaryngo,2003, 123(8): 892.
  • 5Vessslla RL,Pantel K,Mohla S.Tumorcell dormancy:an NCI workshopreport[j].Cancer Biol-Thery, 2007,6(9):1496-1504.
  • 6OzgUven BY, KabuktCuoglu F.Expression of cytokeratin 19,HBME-1 and galectin -3 in eoplastic and non -neoplastic thyroidlesions[j].Pol J Pathol. 2012,63( 1 ):58-64.
  • 7Hong IK, Jin YJ, Byun HJ, et al. Homophilic interactions ofTetraspanin CK151 up Regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways[j]. Biol Chem,2006,281(34): 24279-24292.
  • 8Tomislav Novosel,Hadley E,Ritter, et al.Detection of circulatingthyroid cancel cells in patients with thyroid microcarcinomas [ j].Surgery,2009,61(46):1803-9.
  • 9Chia SY, Milas M.Thyroid-stimulating hormone receptor messengerribonucleic acid measurement in blood as a marker for circulatingthyroid cancer cells and its role in The preoperative diagnosis ofthyroid cancer[J]_ Clin Endocrinol Metab. 2007,92(2):468-75.
  • 10Milas M, Shin JD, Circulating thyrotropin receptor mRNA as a novelmarker of Thy-roid cancer clinical applications learned from 1758samples[j]. Ann Surg. 2010,252(4):643-51.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部